To access the full text documents, please follow this link: http://hdl.handle.net/2445/49763

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
Tricoci, Pierluigi; Cequier Fillat, Àngel R.; Held, Claes; Moliterno, David J.; Armstrong, Paul W.; Ambrosio, Giuseppe; Leonardi, Sergio
Universitat de Barcelona
Background: Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. Methods: In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization. RESULTS: Follow-up in the trial was terminated early after a safety review. After a median follow-up of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 of 6473 patients receiving vorapaxar versus 1102 of 6471 patients receiving placebo (Kaplan-Meier 2-year rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence interval [CI], 0.85 to 1.01; P = 0.07). A composite of death from cardiovascular causes, myocardial infarction, or stroke occurred in 822 patients in the vorapaxar group versus 910 in the placebo group (14.7% and 16.4%, respectively; hazard ratio, 0.89; 95% CI, 0.81 to 0.98; P = 0.02). Rates of moderate and severe bleeding were 7.2% in the vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; P<0.001). Intracranial hemorrhage rates were 1.1% and 0.2%, respectively (hazard ratio, 3.39; 95% CI, 1.78 to 6.45; P<0.001). Rates of nonhemorrhagic adverse events were similar in the two groups. Conclusions: In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage. (Funded by Merck; TRACER ClinicalTrials.gov number, NCT00527943.)
Malalties cardiovasculars
Bypass cardiopulmonar
Plaquetes sanguínies
Medicaments
Cardiovascular diseases
Bypass cardiopulmonary
Blood platelets
Drugs
(c) Massachusetts Medical Society, 2012
Article
info:eu-repo/semantics/publishedVersion
Massachusetts Medical Society
         

Show full item record

Related documents

Other documents of the same author

Tricoci, Pierluigi; Cequier Fillat, Àngel R.; Held, Claes; Moliterno, David J.; Armstrong, Paul W.; Ambrosio, Giuseppe; Leonardi, Sergio
Roura, Gerard; Gómez Lara, Josep; Ferreiro, José Luís; Gómez Hospital, Joan A.; Romaguera, Rafael; Teruel, Luís M.; Carreño, Elena; Esplugas Oliveras, Enrique; Alfonso, Fernando; Cequier Fillat, Àngel R.
Cequier Fillat, Àngel R.; Gómez Hospital, Joan A.; Gonzalez Costello, José
Cequier Fillat, Àngel R.; Gómez Hospital, Joan A.; González-Costello, José
Valgimigli, Marco; Sabaté Tenas, Manuel; Kaiser, Cristoph; Brugaletta, Salvatore; Torre Hernández, José María de la; Galatius, Soeren; Cequier Fillat, Àngel R.; Eberli, Franz; De Belder, Adam; Serruys, P. W.; Ferrante, Giuseppe
 

Coordination

 

Supporters